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Abstract 
Objectives: It can be difficult to differentiate diffuse malignant petitoneal mesothelioma 
(DMPM) from reactive mesothelial hyperplasia (RMH) or peritoneal dissemination of 
gynecological malignancies, such as epithelial ovarian cancer (EOC), which cause a large 
amount of ascites. Detection of the homozygous deletion of p16/CDKN2A (p16) by 
fluorescence in situ hybridization (FISH) is an effective adjunct in diagnosis of malignant 
pleural mesothelioma. The aim of this study was to investigate ability of p16 FISH assay to 
differentiate DMPM from RMH and EOC.  
Methods: p16 FISH was performed in 28 DMPM (successful in 19), 30 RMH and 40 EOC 
cases. The cutoff values of p16 FISH were >10% for homozygous deletion and >40% for 
heterozygous deletion.  
Results: According to the above criteria, 47.4% (9/19) of DMPM cases were homozygous 
deletion-positive and 15.8% (3/19) were heterozygous deletion-positive, whereas all RMH cases 
were negative for p16 deletion. In all four major histological subtypes of EOC, neither p16 
homozygous nor heterozygous deletions were detected. To differentiate DMPM from RMH or 
EOC, the sensitivity of p16 homozygous deletion was 47.4% and the specificity was 100%.  
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Conclusions: Our study suggests that p16 FISH analysis is useful in differentiating DMPM from 
RMH and EOC when homozygous deletion is detected.  
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Introduction 
Malignant mesothelioma is an uncommon and aggressive neoplasm that arises from 
serosal surfaces. In general, these neoplasms have a poor prognosis and short survival.1 After 
the pleura, the peritoneum is the second most frequent site of origin of mesothelioma.2 In female 
patients, the diagnosis of diffuse malignant peritoneal mesothelioma (DMPM) is sometimes 
problematic, because the clinical presentation, diagnostic imaging, and operative findings of 
DMPM are similar to those of epithelial ovarian cancer (EOC), with widespread disease 
throughout the peritoneal cavity.3,4 Malignant mesothelioma also exhibits a wide range of 
histopathological patterns that may potentially mimic a variety of primary and metastatic 
ovarian tumors.3 The distinction between reactive mesothelial hyperplasia (RMH) and DMPM 
is also problematic, because RMH and DMPM have the overlapping morphological findings on 
cytological and surgical specimens.5,6 Although combination of several antibodies as positive- 
and negative-markers for malignant mesothelioma are generally recommended for 
immunohistochemical support of the diagnosis, no satisfactorily reproducible biomarker has yet 
been confirmed.7  
Although no official tumor-node-metastasis (TNM) staging system exists for patients 
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with DMPM, a new staging system was recently proposed. Patients with T1 (peritoneal cancer 
index (PCI) 1-10) N0 M0 survived significantly longer than the other patients, and the 5-year 
survival associated with Stage I, II and III disease was 87%, 53% and 29%, respectively.8 
Furthermore, recent studies suggested that a combination of cytoreductive surgery (CRS) and 
perioperative intraperitoneal chemotherapy (PIC) resulted in improved survival.9,10 Thus, early 
and accurate diagnosis of DMPM is critical for improving its clinical outcome.  
      One of the most common genetic alterations in primary malignant mesothelioma is the 
homozygous deletion of the 9p21 region, which includes CDKN2A/p16INK4a (p16), 
CDKN2B/p15INK4b and p14ARF.11-15 Deletion of the 9p21 region or p16 gene has been reported in 
more than 70 - 80% of mesothelioma by cytogenetic and molecular studies.12-14 Detection of the 
homozygous deletion of p16 by fluorescence in situ hybridization (FISH) was shown to be 
feasible and helpful in confirming a diagnosis of mesothelioma in cytological and surgical 
specimens, especially in the differentiation of malignant pleural mesothelioma from RMH.7,16-25 
Fewer reports are available for p16 FISH in DMPM. However, some studies have reported that 
p16 homozygous deletion, detected by FISH, was found in about 25-51% of DMPM cases.7,22-23 
The aim of this study was to investigate the usefulness and limitations of p16 FISH 
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assay in diagnosis of DMPM, especially in terms of its differentiation from RMH and EOC in 
surgical specimens.  
 
Materials and Methods 
Tissue Samples 
      This study included 28 DMPM cases (14 males and 14 females; mean age, 65.1 years; 
range, 32-72 years), 40 EOC cases (40 females; mean age, 52.9 years; range, 21-74 years) and 
30 RMH cases (30 females; mean age, 50.1 years; range, 21-68 years). The data were derived 
from the peritoneal and gynecological files of the Department of Pathology, Fukuoka University 
Hospital (FUH), in Fukuoka, Japan, and included both FUH and consultation cases from August 
1993 to January 2012. EOC cases were treated at the Department of Obstetrics and Gynecology, 
FUH from July 2006 to June 2011. RMH lesions were obtained from the greater omentum 
excised during gynecological tumor resection to rule out metastatic lesions. All cases were 
histologically diagnosed according to the 2003 WHO classification of tumors of the breast and 
female genital organs.26 The diagnosis of DMPM was confirmed with immunohistochemistry, 
including mesothelial markers [calretinin, WT-1, D2-40, cytokeratin (CK) 5/6], pan-epithelial 
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markers [carcinoembryonic antigen (CEA), Ber-EP4, MOC-31, thyroid transcription factor-1 
(TTF-1)] and others (CAM5.2, CK AE1/AE3, EMA, PAX8). The clinicopathological 
characteristics of the tumor and reactive cases are summarized in Table 1. 
 
Fluorescence In Situ Hybridization (FISH) analysis 
p16 FISH was performed on formalin-fixed, paraffin-embedded, 4-µm-thick tissue 
sections using DAKO Histology FISH Accessory Kit (DAKO, Carpinteria, CA) with slight 
modifications as described previously.25 Briefly, sections were deparaffinized and rehydrated 
with descending alcohol dilutions. This was followed by treatment with 2×saline-sodium citrate 
(2×SSC) containing 0.3% Tween 20 (Sigma, St Louis, MO), washed with 2×SSC, and then 
treated with pretreatment solution (20× dilution) at 95°C for 10 min and digested with pepsin 
solution at 37°C for 5 minutes. After refixtation in 10% buffered formalin at room temperature 
for 3 min, the tissue sections were treated in 2×SSC containing 0.3% Tween 20 at 45°C for 10 
min, dehydrated in ethanol, dried, and exposed to the two probes [p16 and CEP9 (Abbott Japan, 
Tokyo, Japan)]. Both the probes and tissue sections were denatured at 85°C for 5 min in probe 
solution (Abbott Japan), followed by hybridization at 37°C for 24 hours in ThermoBrite (Abbott 
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Japan). The tissue sections were washed in 2×SSC containing 0.3% Tween 20 at 72°C for two 
minutes and in 2×SSC containing 0.1% Tween 20 at room temperature for 5 minutes. Nuclei 
were counterstained with 4′,6-diamidino-2-phenylindole (DAPI)/antifade (Vector Laboratories, 
Burlingame, CA). Analyses were performed using a fluorescence microscope (Axio Imager Z1; 
Carl Zeiss Microimaging, Jena, Germany) and Isis analysis system (Metasystems, Altlussheim, 
Germany) equipped with filter sets with single and dual band excitors for Spectrum Green, 
Spectrum Orange, and DAPI. Lymphocytes in each section served as internal controls and 
showed 2 signals per FISH probe. Homozygous deletion was defined as lack of both p16 signals 
in the presence of both CEP9 green signals. Heterozygous deletion was assumed when only one 
p16 signal was present, or when the total number of p16 signals did not exceed half the total 
number of the centromeric signals. At least 60 cells were scored in each case. 
 
Statistical Analysis 
      Statistical comparison of FISH data between DMPM and RMH or EOC was performed 
using the Mann-Whitney U test. A P-value < 0.05 was considered statistically significant. All 
statistical evaluations were performed with StatMate IV statistical software for Windows 
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(ATMS Co., Tokyo, Japan). 
 
Results 
      To determine the rate of p16 deletion DMPM, RMH, and EOC cases, we first 
systematically performed histological and FISH analyses on samples from each case. Image 1 
shows representative H&E sections and FISH images of epithelioid type DMPM (Image 1A, B) 
and RMH (Image 1C, D). In DMPM, p16FISH analysis was successful in 19 of 28 cases 
(67.9%). The remaining nine surgical or autopsy samples that failed were collected from 1993 
to 1998 pathology files. These samples could not be analyzed because the signal intensity was 
too low. The 19 successful cases included 7 males (36.8%) and 12 females (63.2%). 
Mesothelioma cells with homozygous deletion of p16 showed loss of two red signals (Image 
1B), while RMH cells exhibited two red and two green signals (Image 1D). In 30 cases of RMH, 
p16 homozygous and heterozygous deletions were observed in 1.7±2.1% and 17.6±7.7% of 
cells, respectively, whereas normal pattern was observed in 80.3±8.9% of cells (Figure 1A).  
To determine whether p16 deletion could differentiate between DMPM and RMH, we 
performed statistical analysis comparing the rates of deletion between the two groups. The 
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cutoff values for homozygous and heterozygous deletions were calculated as the mean 
percentage + 3 standard deviations (SDs), and set >10% for homozygous deletion and >41% for 
heterozygous deletion, based on the results in RMH. According to these criteria, 9/19 cases 
(47.4%) of DMPM were homozygous deletion-positive and 4/19 cases (21.0%) of DMPM were 
heterozygous deletion-positive, whereas all RMH cases were negative for p16 deletion (Figures 
1A and 1B). All of the four heterozygous deletion-positive cases were also homozygous 
deletion-positive. Analysis of all cases (Figure 1B) and female-only cases (Figure 1C) of 
DMPM showed significantly more frequent homozygous deletion than RMH cases (P < 0.05, 
Mann-Whitney U test) (Figure 1C). These data suggest that homozygous deletion of p16 is 
indicative of DMPM over RMH. 
Finally, we investigated whether p16 homozygous deletion could differentiate between 
DMPM and EOC. Image 2 shows representative H&E sections of EOC (Image 2A, serous 
adenocarcinoma; Image 2C, mucinous adenocarcinoma; Image 2E, endometrioid 
adenocarcinoma; Image 2G, clear cell adenocarcinoma). These carcinoma cells mostly showed 
the normal p16 FISH pattern (Image 2B, 2D, 2F and 2H). In all cases of EOC (n=40), the mean 
rates of homozygous and heterozygous deletions were 7.9% and 15.4%, respectively (Figure 2). 
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None of EOC cases (0/40) was p16 homozygous or heterozygous-deletion positive (Figure 2A). 
When divided into histological subtypes no single subtype of EOC exceeded the cutoff values 
for homozygous or heterozygous deletion (Figure 2B). Finally, we compared female cases of 
DMPM with EOC cases and found that homozygous deletion was significantly more frequent in 
DMPM than EOC (P< 0.05, Mann-Whitney U test) (Figure 2C). Overall, when differentiating 
DMPM from RMH and EOC, the sensitivity of p16 homozygous deletion detected by FISH was 
47.4%, while the specificity was 100% (Table 2). Based on these results, we conclude that p16 
homozygous deletion is a useful tool to confirm that a case is DMPM over RMH or EOC, but in 
cases where p16 homozygous deletion is lacking, a diagnosis of DMPM cannot be ruled out. 
 
Discussion 
      To the best of our knowledge, this is the first report to describe the usefulness and 
limitations of p16 FISH analysis in the differentiation of DMPM from RMH and EOC. Based 
on our study design, p16 homozygous deletion was found in 47.4% (9/19) of DMPM cases, 
whereas none of RMH and EOC lesions exhibited the homozygous deletion. Even when 
considered by their major histological subtypes (serous, mucinous, endometrioid and clear cell 
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adenocarcinoma), all EOC cases were p16 deletion-negative. Thus, when homozygous deletion 
is positive, p16 FISH can reliably differentiate DMPM from RMH and EOC. Although the 
sensitivity of p16 homozygous deletion detected by FISH was 47.4%; its specificity was high 
(100%), making p16 FISH a useful ancillary tool in cases where homozygous deletion is 
positive.  
      Other studies have shown that p16 FISH is useful in the differentiation of pleural 
mesothelioma from RMH; p16 homozygous deletion was detected in 43-92% of pleural 
mesothelioma, whereas none of RMH cases were deletion positive.7,16-25 Correct diagnosis of 
mesothelioma requires the detection of invasion of stroma and/or adipose tissue, but this is 
difficult in small biopsy specimens and/or effusion cytology.27 Moreover, no reliable 
immunohistochemical markers have been established to differentiate diffuse malignant 
mesothelioma from benign mesothelial proliferations. The significance of a recently recognized 
marker of malignancy, GLUT-1, in malignant mesothelial proliferations remains to be 
validated.7 In these circumstances, p16 homozygous deletion was shown to be a very powerful 
technique; the diagnosis of mesothelioma over reactive mesothelial cells was confirmed in most 
patients with positive or suspicious cytology.16 In DMPM, the positive rate of p16 homozygous 
Page 19 of 33
33 W. Monroe, Suite 1600, Chicago, IL 60603
American Journal of Clinical Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  13
deletion is lower, ranging from 25-51%.7,22-23 However, all peritoneal RMH cases were deletion 
negative, the same as pleural RMH cases. Our study confirmed these studies, with a positive 
rate 47.4% of p16 homozygous deletion in DMPM and no RMH cases positive for homozygous 
deletion. This 100% specificity makes p16 FISH reliable, despite a lower sensitivity. 
      The presence of malignant ascites is a sign of malignant cells in the peritoneal cavity. 
DMPM is often associated with massive or bloody malignant ascites. However, the malignant 
ascites are caused more commonly by secondary peritoneal surface malignancies, which include 
ovarian, colorectal, pancreatic, uterine and extra-abdominal tumors originating from lymphoma, 
lung and breast.28 In the female peritoneum, EOC is one common cause of malignant ascites 
formation. The distinction between EOC and DMPM is important for proper clinical 
management and to predict a prognosis. The prognosis of EOC has been improving by use of 
both neoadjuvant and adjuvant chemotherapy, whereas DMPM remains a radio- and 
chemo-resistant malignant neoplasm with a poor prognosis.28,29 Although peritoneal effusion 
cytology and/or peritoneal biopsy is an universal method for differential diagnosis of peritoneal 
malignancies, diagnostic distinction only based on morphologies obtained by H&E staining or 
Papanicolaou staining is often difficult. Recently, combinations of positive and negative 
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immunohistochemical markers were proposed for the differential diagnosis between EOC and 
DMPM, but there is still much controversy as to the value of the different immunohistochemical 
markers and their combinations.29,30 In this study, p16 homozygous deletion showed specificity 
of 100% for the differentiation of DMPM from EOC. Moreover, the specificity was also 100% 
for distinction of DMPM from RMH as described above. Thus, once a lesion is confirmed to 
have a p16 homozygous deletion, it is very useful in the differential diagnosis of DPMM from 
EOC and RMH. 
      Homozygous deletion of the 9p21 locus, which contains p16, was reported in cell lines 
derived from many types of human tumors, including lung (59%), breast (10%), brain (35%), 
bladder (15%) and ovary (29%). Thus, a role of p16 in human tumorigenesis has been 
suggested.31 One study suggested that p16 inactivation by homozygous deletion or mutation was 
rare in ovarian tissues (in 2/70 and 4/70 EOC, respectively).32 In that study, the inactivation of 
p16, as detected by loss of p16 mRNA and protein expression, was a consequence of 
hypermethylation of the 5’-CpG island, rather than by gene deletion or point mutation.32 
Similarly, neither deletions nor rearrangements of the p16 gene were detected by Southern blot 
hybridization in ovarian cancer tissues (0/20), and only 4% of them showed altered migration 
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(gene alterations) on single-strand conformation polymorphism (SSCP).33 Thus, it seems likely 
that p16 inactivation by epigenetic mechanisms such as hypermethylation, but not by gene 
alterations, may play an important role in the formation of human EOC.32 Our results, which 
showed no homozygous deletion of p16 in the 40 tested EOC cases, are in agreement with these 
known reports and their hypotheses.  
      The use of p16 FISH in differentiation of DMPM from other malignancies with 
peritoneal spreading has some limitations. Both pancreatic ductal adenocarcinoma (PDAC) and 
cholangiocarcinoma (CCA) of the liver, which may cause malignant ascites, have p16 
homozygous deletion in as many as 50% of cases, similar to that of DMPM.34,35 Thus, 
application of p16 FISH is of no use in the differentiation between DMPM and PDAC or 
DMPM and CCA. p16 FISH can be a useful and reliable adjunct for differentiating DMPM 
from other malignancies by understanding its benefits and limitations. 
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Image and Figure Legends 
Image 1. Histology and p16 FISH in DMPM and RMH. (A), Epithelioid type of DMPM. The 
cells are arranged in papillotubular structures with fibrovascular stroma. (B), p16 FISH 
demonstrating homozygous deletions (loss of two red signals per cell). (C), An RMH case that 
shows a mild piling up of reactive mesothelial cells. (D), p16 FISH that shows a normal pattern 
(two red and two green signals). (A) and (C): H&E, ×200; (B) and (D): FISH, ×630. DMPM, 
diffuse malignant peritoneal mesothelioma; RMH, reactive mesothelial hyperplasia.  
 
Image 2. Subtypes of EOC and their representative p16 FISH patterns. (A), Serous 
adenocarcinoma showing proliferation of high-grade serous carcinoma cells arranged in 
irregular papillary structures. (C), Mucinous adenocarcinoma, in which atypical mucinous cells 
are arranged in irregular papillotubular structures. (E), Endometrioid adenocarcinoma showing 
proliferation of atypical endometrial-like cells arranged in irregular fused tubular structures. 
(G), Clear cell adenocarcinoma, in which atypical cells with clear cytoplasm and rounded nuclei 
proliferate forming irregular papillotubular structures. (B), (D), (F) and (H), p16 FISH, 
predominantly demonstrating normal pattern with two red and two green signals. (A), (C), (E) 
and (G): H&E, ×200; (B), (D), (F) and (H): FISH, ×630. EOC, epithelial ovarian cancer.  
 
Figure 1. p16 FISH patterns in surgical specimens. Data are given as mean ± standard deviation 
for RMH cases (A), all DMPM cases (B) or female DMPM cases (C). In (C), p16 FISH patterns 
in RMH and female cases of DMPM are compared. Data are number of cells exhibiting each 
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p16 FISH pattern. Dotted lines represent the mean; solid lines represent mean + 3 standard 
deviations. Based on the results shown in RMH cases (A), the cutoff values for homozygous 
and heterozygous deletions were set at 10% and 40%, respectively. Open circle, RMH cases; 
solid circle, all (B) or female (C) cases of DMPM; FISH, fluorescence in situ hybridization; 
RMH, reactive mesothelial hyperplasia; DMPM, diffuse malignant peritoneal mesothelioma.   
 
Figure 2. p16 FISH patterns in surgical specimens of EOC cases. Data are given as mean ± 
standard deviation for all cases (A) and each histological subtype (B). In (B), SA = serous 
adenocarcinoma; MA = mucinous adenocarcinoma; EA = endometrioid adenocarcinoma; CA = 
clear cell adenocarcinoma. In (C), p16 FISH patterns in EOC (all cases) and female cases of 
DMPM are compared. Solid circle, female cases of DMPM; open rhombus, EOC. Data are 
number of cells exhibiting each p16 FISH pattern. The mean for each group is denoted with a 
dotted line. The cutoff values for homozygous and heterozygous deletions were set at 10% and 
40%, respectively (solid lines). FISH, fluorescence in situ hybridization; EOC, epithelial 
ovarian cancer; DMPM, diffuse malignant peritoneal mesothelioma. 
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Table 1.  
Clinicopathological characteristics of 98 cases. 
Characteristics DMPM             EOC RMH 
Number 28 40 30 
Sex    
 Male/Female 14/14 0/40 0/30 
Mean age (range) 
  Male 
 Female 
65.1 (32-78) 
66.8 (61-77) 
63.7 (32-78) 
52.9 (21-74) 50.1 (21-68) 
Histological type Epithelioid, 22 (12/10)     Serous, 10  
  Biphasic, 4 (0/2)     Mucinous, 10  
 Sarcomatoid, 2 (2/2)     Endometrioid, 10  
      Clear cell, 10  
Rate of successful p16 
FISH    
19/28 (67.9%) 
 
40/40 (100%) 30/30 (100%) 
FISH, fluorescence in situ hybridization; DMPM, diffuse malignant peritoneal mesothelioma; 
EOC, epithelial ovarian cancer; RMH, reactive mesothelial hyperplasia; Serous, serous 
adenocarcinoma; Mucinous, mucinous adenocarcinoma; Endometrioid, endometrioid 
adenocarcinoma; Clear cell, clear cell adenocarcinoma. 
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 Table 2.   
Sensitivity and specificity of p16 FISH in differentiation of DMPM from RMH and EOC.  
 Homozygous deletion   
 Positive Negative Sensitivity Specificity 
DMPM 47.4% (9/19) 52.6% (10/19) 47.4% 100% 
RMH 0% (0/30) 100% (30/30) 0% 100% 
EOC 0%(0/40) 100% (40/40) 0% 100% 
FISH, fluorescence in situ hybridization; DMPM, diffuse malignant peritoneal 
mesothelioma; RMH, reactive mesothelial hyperplasia; EOC, epithelial ovarian cancer. 
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